Table 5.
Clinical outcomes of COVID-19 between AAP and NSAIDs.
| Variables | AAP n = 162 |
NSAIDs n = 162 |
p-Value * |
|---|---|---|---|
| (a) Risk of composite endpoint 1 and 2 | |||
| Composite endpoint 1, n (%) | 0.776 | ||
| No | 130 (80.2) | 133 (82.1) | |
| Yes | 32 (19.8) | 29 (17.9) | |
| Composite endpoint 2, n (%) | 0.587 | ||
| No | 143 (88.3) | 147 (90.7) | |
| Yes | 19 (11.7) | 15 (9.3) | |
| (b) Risk or serious COVID-19 outcomes (composite endpoint 1) | |||
| Conventional oxygen therapy | 0.874 | ||
| No | 138 (85.2) | 140 (86.4) | |
| Yes | 24 (14.8) | 22 (13.6) | |
| Intensive care unit | 0.720 | ||
| No | 159 (98.1) | 157 (96.9) | |
| Yes | 3 (1.9) | 5 (3.1) | |
| Mechanical ventilation | 1.000 | ||
| No | 154 (95.1) | 155 (95.7) | |
| Yes | 8 (4.9) | 7 (4.3) | |
| Death | 0.344 | ||
| No | 150 (92.6) | 155 (95.7) | |
| Yes | 12 (7.4) | 7 (4.3) | |
*: Pearson’s chi-square test; composite endpoint 1: conventional oxygen therapy, intensive care unit, mechanical ventilation, or death.; composite endpoint 2: intensive care unit, mechanical ventilation, or death.